Table 1 Baseline characteristics of 525 children and adolescents with community acquired pneumonia and 61 controls
Variables | CAP group (N = 525) | Control group (N = 61) |
|---|---|---|
Age in months, median (IQR) | 32 (14–53) | 53 (29–72) |
n/N (%) | ||
Age by groups | ||
0–23 months | 206/525 (39.2) | 12/61 (19.7) |
2–4 years | 213/525 (40.6) | 23/61 (37.7) |
≥5 years | 106/525 (20.2) | 26/61 (42.6) |
Male | 267/525 (50.9) | 44/61 (72.1) |
Urban area | 401/525 (76.4) | 61/61 (100) |
Vaccination record (according to card available) | 417/525 (79.4) | 25/61 (41.0) |
Pentavalent vaccine (DPT, Hep B, Hib) | 400/415 (96.4) | 25/25 (100) |
Fully vaccinated for age | 375/404 (92.8) | 23/25 (92.0) |
Pneumococcal vaccinea | 197/416 (47.4) | 16/25 (64.0) |
0–23 months | 107/173 (61.8) | 6/16 (37.5) |
2–4 years | 73/176 (41.5) | 6/16 (37.5) |
≥5 years | 17/67 (25.4) | 4/16 (25.0) |
Influenza vaccine | 172/410 (42.0) | 18/25 (72.0) |
Any associated condition | 154/523 (29.4) | ND |
Asthma | 139/523 (26.6) | – |
Othersb | 23/523 (4.4) | – |
History of prior antibiotics in the last 3 months | 121/522 (23.2) | 6/61 (9.8) |
Prior antibiotics in the last 48 h | 38/523 (7.3) | 0 (0) |
Prior hospitalization due to pneumonia | 138/523 (26.4) | ND |
< 3 months | 21/138 (15.2) | – |
3 months – 11 months | 63/138 (45.7) | – |
≥1 year | 54/138 (39.1) | – |